drugset / Trial / NCT02115152
Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer
RandomizedFactorialOpen-labelTreatment
Summary
This randomized phase II trial compared pathologic response rates (pCR) of early breast cancer following neoadjuvant fluorouracil-epirubicin-cyclophosphamide(FEC) and capecitabine-epirubicin-cyclophosphamide (XEC).
Timeline
- Start
- 2014-06
- Primary completion
- 2018-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Comparator | fluorouracil | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Epirubicin | Small molecule | — | — |